• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
water filter
WATER FILTER FOR WATER PURIFIER
DUST BAG
Small dust filter
HUMIDIFIER FILTER
Oil fume adsorption filter

Italy's AIFA approves using different vaccine for second dose after AstraZeneca jab

firstwordpharmaJune 15, 2021

Tag: AstraZeneca , COVID-19 , Vaccine

Italy's medicine agency AIFA said Italians under the age of 60 who received a first dose of the AstraZeneca COVID-19 vaccine Vaxzevria can be given a different vaccine when they get their second dose, as reported in Yahoo!News.

Italy's AIFA approves using different vaccine for second dose after AstraZeneca jab

Last week, Italy restricted the use of Vaxzevria to people over the age of 60, after a teenager who had received the shot died from a rare form of blood clotting.

"Based on clinical studies published in the last few weeks, AIFA's scientific committee has decided to approve the vaccine mix," AIFA said in a statement, adding vaccines developed by Pfizer and Moderna could be administered to people who first got an AstraZeneca jab.

Previous:Weight-Loss Surgeries Used Least in U.S. States That Need Them Most

Next:Good News, Bad News From Alzheimer's Vaccine Trial

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Italy's AIFA approves using different vaccine for second dose after AstraZeneca jab | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Hualan's Trivalent Flu Vaccine

Hualan's Trivalent Flu Vaccine
Hualan H7N9 Inactivated Influenza Vaccine by Hualan Bio

Hualan H7N9 Inactivated Influenza Vaccine by Hualan Bio
Hualan Biological inactivated influenza vaccine

Hualan Biological inactivated influenza vaccine
Hualan Biological Recombinant Hepatitis B Vaccine (Hansenula polymorpha)with High purity and good s

Hualan Biological Recombinant Hepatitis B Vaccine (Hansenula polymorpha)with High purity and good s
Freeze-Dried Live Attenuated Varicella Vaccine

Freeze-Dried Live Attenuated Varicella Vaccine
Influenza Vaccine(Split Virion),Inactivated

Influenza Vaccine(Split Virion),Inactivated
Hualan Bio Meningococcal Polysaccharide Vaccine Group ACYW135

Hualan Bio Meningococcal Polysaccharide Vaccine Group ACYW135
Swine Vaccine Series

Swine Vaccine Series
Quadrivalent Influenza Vaccine in 2022

Quadrivalent Influenza Vaccine in 2022
Influenza Vaccine by Hualan Bio

Influenza Vaccine by Hualan Bio

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service